Synthorx to Present at the 2019 World Congress of Inflammation
September 09 2019 - 8:00AM
Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology
company developing optimized therapeutics for cancer and autoimmune
disorders, today announced the details of a scientific presentation
characterizing THOR-809, a Synthorin™ for the treatment of
autoimmune diseases, at the 2019 World Congress of Inflammation,
taking place in Sydney, Australia. The presentation will be held on
Tuesday, September 17th.
Marcos Milla, Ph.D., chief scientific officer of Synthorx, will
present the company’s approach to utilizing its first-of-its-kind
Expanded Genetic Alphabet platform technology to engineer THOR-809
for the treatment of autoimmune disorders. THOR-809 is a
site-specific, covalently-bound, monopegylated IL-2 Synthorin that
selectively expands peripheral CD4+ regulatory T cells (Tregs) in
preclinical models.
“Targeting IL-2 is an exciting approach for treating autoimmune
disorders, given its role in stimulating the regulatory T cells
that induce the body’s tolerance to autoantigens,” said Dr. Milla.
“The discovery of THOR-809 showcases our platform’s versatility in
fine-tuning notoriously difficult proteins—such as IL-2—to optimize
their pharmacological properties. Based on preclinical data that we
have generated, we believe that THOR-809 has the potential to
produce a differentiated profile due to its robust peripheral Treg
expansion, the absence of natural killer and effector T cell
expansion, and improved half-life.”
Details of the presentation are as follows:
Title: THOR-809: An
IL-2 engineered from an expanded genetic alphabet for the potential
treatment of autoimmune (AI) disordersPresenter:
Marcos Milla, Ph.D.Session Date: Tuesday,
September 17th, 2019 Time: 11:45AM – 11:50AM
Australian Eastern Standard TimeLocation: Parkside
Ballroom at the International Convention Centre, Sydney
A copy of the materials will be available at the time of the
presentation and archived in the Scientific Publications section of
the Synthorx website.
About SynthorxSynthorx, Inc. is a
clinical-stage biotechnology company focused on prolonging and
improving the lives of people with cancer and autoimmune disorders.
Synthorx’ proprietary, first-of-its-kind Expanded Genetic Alphabet
platform technology expands the genetic code by adding a new DNA
base pair and is designed to create optimized biologics, referred
to as Synthorins. A Synthorin is a protein optimized through
incorporation of novel amino acids encoded by the new DNA base pair
that enables site-specific modifications, which enhance the
pharmacological properties of these therapeutics. The company’s
lead product candidate, THOR-707, a variant of IL-2, is in
development in multiple tumor types as a single agent and in
combination with an immune checkpoint inhibitor. The company was
founded based on important discoveries by Dr. Floyd Romesberg and
The Scripps Research Institute. Synthorx is headquartered in La
Jolla, Calif. For more information, visit www.synthorx.com.
Forward-Looking Statements This press release
contains forward-looking statements about Synthorx as that term is
defined in Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934. Statements in this
press release that are not purely historical are forward-looking
statements. Such forward-looking statements include, among other
things, preclinical data or plans underlying THOR-809 and the
development of Synthorx’s product candidates. Actual results could
differ from those projected in any forward-looking statements due
to numerous factors. Such factors include, among others, risks
associated with the process of discovering, developing and
commercializing drugs that are safe and effective for use as human
therapeutics and operating as a development stage company;
Synthorx’s ability to develop, initiate or complete preclinical
studies and clinical trials for, obtain approvals for and
commercialize any of its product candidates; changes in Synthorx’s
plans to develop and commercialize its product candidates; the
potential for any future clinical trials of THOR-809 or other
product candidates to differ from preliminary or expected results;
Synthorx’s ability to raise any additional funding it will need to
continue to pursue its business and product development plans;
regulatory developments in the United States and foreign countries;
Synthorx’s reliance on key third parties, including contract
manufacturers and contract research organizations; Synthorx’s
ability to obtain and maintain intellectual property protection for
its product candidates; the loss of key scientific or management
personnel; competition in the industry in which Synthorx operates;
and market conditions. These forward-looking statements are made as
of the date of this press release, and Synthorx assumes no
obligation to update the forward-looking statements, or to update
the reasons why actual results could differ from those projected in
the forward-looking statements. Investors should consult all of the
information set forth herein and should also refer to the risk
factor disclosure set forth in the documents the company files with
the SEC available at www.sec.gov.
Investor Contacts:
Enoch Kariuki, Pharm.D.
Synthorx, Inc.
ekariuki@synthorx.com
858-750-4750
Christina Tartaglia
Stern Investor Relations
christina.tartaglia@sternir.com
212-362-1200
Media Relations Contact:
Lauren Fish
Canale Communications
lauren@canalecomm.com
619-849-5386
Synthorx (NASDAQ:THOR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Synthorx (NASDAQ:THOR)
Historical Stock Chart
From Sep 2023 to Sep 2024